CEACAM5 and metastatic colorectal cancer: Using a novel technology to redirect the specificity of T cells, we evaluated the efficacy of a CEA/CD3- bispecific antibody of the BiTE class against human colorectal cancer cell lines and metastatic colorectal cancer explants.